Adronic

Adronic (Zoledronic Acid)

Indications

Zoledronic Acid is a bisphosphonate indicated for the treatment of:
• Hypercalcemia of malignancy.
• Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
Limitation of use: The safety and efficacy of Zoledronic Acid have not been established for use in hyperparathyroidism or nontumor-related hypercalcemia.

Dosage & Administration

Hypercalcemia of malignancy
• 4 mg as a single-use intravenous infusion over no less than 15 minutes.
• 4 mg as retreatment after a minimum of 7 days.
Multiple myeloma and bone metastasis from solid tumors
• 4 mg as a single-use intravenous infusion over no less than 15 minutes every 3-4 weeks for patients with creatinine clearance of greater than 60 ml/min.
• Reduce the dose for patients with renal impairment.
• Coadminister oral calcium supplements of 500 mg and a multiple vitamin containing 400 international units of Vitamin D daily.
Administer through a separate vented infusion line and do not allow to come in contact with any calcium or divalent cation-containing solutions.

Side effects

The most common adverse events (greater than 25%) are nausea, fatigue, anemia, bone pain, constipation, fever, vomiting, and dyspnea.

Description

The active ingredient in Adronic is Zoledronic Acid, which belongs to a group of medicines called bisphosphonates. It is an inhibitor of osteoclast-mediated bone resorption. The action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered Zoledronic Acid is rapidly distributed to bone. Zoledronic Acid is not metabolized and is excreted unchanged via the kidney.